Pharmacological modulation of the diabetic gut microbiome with gliflozin drugs:new insights for therapeutic targeting
Abstract
This review explores the relationship between gut microbiota, diabetes, and the potential of SGLT2 inhibitor drugs (gliflozins) in improving gut health and overall metabolic status. Gut microbiota plays a crucial role in regulating processes such as digestion, immunity, and homeostasis. Disruptions in the balance of this microbial community can lead to various health issues, including diabetes. In diabetic patients, changes in bacterial composition are observed, such as an increase in harmful bacteria (Firmicutes) and a decrease in beneficial bacteria (Bacteroidetes). SGLT2 inhibitors, including empagliflozin, canagliflozin, and dapagliflozin, have positive effects on gut microbiota in addition to lowering blood sugar levels. These drugs work by promoting the growth of beneficial bacteria such as Lactobacillus and Bifidobacterium and increasing the production of short-chain fatty acids (SCFAs), which are essential for gut health. Furthermore, by reducing harmful bacteria, they help mitigate diabetic complications, such as kidney damage, heart problems, and liver fibrosis. However, the long-term effects of these drugs on gut microbiota remain unclear, and individual responses may vary based on factors like genetics, diet, and lifestyle. Combining these drugs with probiotics, prebiotics, or dietary modifications could enhance their efficacy and offer a more personalized approach to treatment. Gliflozins contribute to this shift by rebalancing the body's systems. As research…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.